Is SGNT a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

121 people get SGNT articles and Market Currents by email alert.

Get email alerts on SGNT »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Sagent Pharmaceuticals IPO Preview
IPOdesktop • Mon, Apr 18, 2011

To learn more about Seeking Alpha Pro, click here.

China Biotech In Review: Sagent Buys Out China JV Partner For $25 Million
ChinaBio Today • Sun, May 12
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
2 Biotech Short-Squeeze Candidates For The New Year
EnhydrisPECorp • Mon, Dec 31, 2012 • 9 Comments
4 Highly Liquid Small Cap Healthcare Stocks Set For Growth
ZetaKap • Tue, Sep 4, 2012 • 3 Comments
8 Highly Liquid Small Caps Being Bought Up By Hedge Funds
Kapitall • Sat, Jul 28, 2012
How And When To Know Which IPOs To Invest In
Brian Nichols • Sun, Dec 18, 2011 • 5 Comments
20 Healthcare Stocks With Strong Sales Trends
Kapitall • Thu, Dec 1, 2011
Biotech IPO Class of 2011 Takes Drubbing
The Burrill Report • Sun, Aug 14, 2011
Consumer IPOs Defy Bad Economic Data
Renaissance Capital IPO Research • Mon, Aug 1, 2011 • 2 Comments
Last Week in Global IPOs: IPOX Indexes Trading Higher, U.S. IPOs Outperforming Hong Kong
Josef Schuster • Tue, Apr 26, 2011
The IPO Buzz for the Week of April 25, 2011
IPOScoop • Tue, Apr 26, 2011
5 IPOs Post Positive Returns
Renaissance Capital IPO Research • Sun, Apr 24, 2011 • 2 Comments
This Week's IPO Buzz: From China to the Cloud
IPOScoop • Thu, Apr 21, 2011
6 IPOs Planned for the Week of April 18
Renaissance Capital IPO Research • Mon, Apr 18, 2011

There are no Transcripts on SGNT.

Sagent Pharmaceuticals Expands a Nationwide Voluntary Recall to All Lots of Vecuronium Bromide for Injection, 10mg Single Use Vials Manufactured by Mustafa Nevzat (MN Pharmaceuticals)

GlobeNewswire (Thu, 9:45AM)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Vecuronium Bromide for Injection, 10mg Manufactured by Mustafa Nevzat (MN Pharmaceuticals) Due to Elevated Impurity Levels

GlobeNewswire (Jun 7, 2013)
Sagent Pharmaceuticals Reports First Quarter 2013 Financial Results

GlobeNewswire (May 6, 2013)
Sagent Pharmaceuticals Announces Agreement to Acquire Remaining 50% Interest in Chinese Manufacturing Joint Venture

GlobeNewswire (May 6, 2013)
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2013 Financial Results

GlobeNewswire (Apr 24, 2013)
Sagent Pharmaceuticals Appoints James M. Hussey as President

GlobeNewswire (Mar 19, 2013)
Sagent Pharmaceuticals Announces Amendment to Supply Agreement With Actavis, Inc.

GlobeNewswire (Mar 5, 2013)
Sagent Pharmaceuticals Announces the Approval and Launch of Zoledronic Acid Injection 4 mg in a Plastic Vial

GlobeNewswire (Mar 5, 2013)
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Results

GlobeNewswire (Feb 14, 2013)
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Jan 31, 2013)
Sagent Pharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare Conference

GlobeNewswire (Jan 4, 2013)
Sagent Pharmaceuticals Announces the Launch of Flumazenil Injection, USP

GlobeNewswire (Jan 2, 2013)
Sagent Pharmaceuticals Announces Launch of Nafcillin for Injection, USP

GlobeNewswire (Nov 28, 2012)
Sagent Pharmaceuticals Ranked Third Fastest Growing Company in North America on Deloitte's 2012 Technology Fast 500

GlobeNewswire (Nov 19, 2012)
Sagent Pharmaceuticals Announces the Launch of Acetazolamide for Injection, USP

GlobeNewswire (Nov 13, 2012)
Sagent Pharmaceuticals Reports Third Quarter 2012 Financial Results

GlobeNewswire (Nov 8, 2012)
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection

GlobeNewswire (Oct 29, 2012)
Sagent Pharmaceuticals Sets Date and Time for Release of Third Quarter 2012 Financial Results

GlobeNewswire (Oct 25, 2012)
Sagent Pharmaceuticals Announces the Launch of Caffeine Citrate Injection, USP and Caffeine Citrate Oral Solution, USP

GlobeNewswire (Oct 3, 2012)
Sagent Pharmaceuticals Announces the Launch of Vancomycin Hydrochloride for Injection, USP

GlobeNewswire (Sep 28, 2012)

SGNT vs. ETF Alternatives

Company Description

Currently, there's no company description for SGNT.

Sector: Healthcare

Industry: Drugs - Generic

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, June 7, 3:24 PM Sagent Pharmaceuticals (SGNT +0.7%) says it's initiated a voluntary nationwide recall of three lots of Vecuronium Bromide for Injection due to the discovery of an elevated impurity detected during routine quality testing of stability samples. The elevated impurity has the potential to result in prolonged neuromuscular blockade for critically ill patients with renal failure. The company said it is not aware of any adverse patient events resulting from the use of this product and will continue its investigation. Comment! [Healthcare, On the Move]
Monday, May 6, 2:47 PM Sagent Pharmaceuticals (SGNT -0.2%) gives back an early 9% lead to trade back into the red today following an earlier Q1 earnings beat and the announcement that it's acuired the remaining 50% interest in its China joint venture Kanghong Sagent Pharmaceutical for $25M. The company also says it expects FY13 net revenue to be around $220M to $250M, and net income to be between $5M and $15M. Street estimates are for the company to report revenue of $238M and net income of $2.4M. Comment! [Healthcare, Earnings, On the Move]
Monday, May 6, 7:17 AM Sagent Pharmaceuticals (SGNT): Q1 EPS of $0.34. Revenue of $60.2M beats by $4.89M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, March 5, 6:17 PM Sagent Pharmaceuticals (SGNT) announces the approval and launch of its Zoledronic Acid Injection, the generic form of Zometa, in a plastic vial. The U.S. market for Zoledronic Acid Injection is approximately $606M. Additionally, the company says its amended its manufacturing and supply agreement with Actavis (ACT) which provides for an enhanced profit split in favor of SGNT, plus a revised line-up of products and a one-time termination fee of $5 million payable to Sagent. Comment! [Healthcare]
Thursday, February 14, 7:59 AM Sagent Pharmaceuticals (SGNT): Q4 EPS of $0.00 beats by $0.20. Revenue of $53.2M (+10% Y/Y) beats by $2M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, January 9, 4:13 PM Sagent Pharmaceuticals (SGNT) says that due to the current shortage of Sodium Bicarbonate Injection in the U.S. market, it's cooperating with the FDA to initiate the temporary importation of a non-FDA approved 8.4% Sodium Bicarbonate Injection from Australian manufacturer Phebra Pty. Comment! [Healthcare]
Friday, August 10, 2012, 2:41 PM Wall Street firms are responding today to Sagent Pharmaceuticals' (SGNT -2.6%) revised outlook yesterday, which took the shares down over 25% during the trading session. RBC cut the shares to Sector Perform on the news, citing a lack of earnings visibility over the near term, while Needham, cut its price target to $20 from $25, saying the company "remains its own worst enemy" when it comes to managing estimates and maintaining management's credibility. Comment! [Healthcare, On the Move]
Wednesday, August 31, 2011, 4:26 PM Sagent Pharmaceuticals (SGNT) receives FDA approval for its Orphenadrine Citrate Injection, USP, a skeletal muscle relaxant. Shares +0.1% AH. Comment! [Healthcare, On the Move]
Tuesday, August 30, 2011, 2:16 PM Shares of Sagent Pharmaceuticals (SGNT -5%) lose ground after the drugmaker appoints a new CFO, and repositions its current exec manning the office to a newly created role. Shares are off 21% in the last month. Comment! [Healthcare]
Friday, August 19, 2011, 4:32 PM Sagent Pharmaceuticals (SGNT +4%) closed higher today after announcing the launch of its neuromuscular blocking agent vecuronium bromide - which is currently in short supply in the U.S. - for injection in 10 and 20 mg single-use vials. Comment! [Healthcare, On the Move]
Thursday, June 23, 2011, 10:57 AM Needham downgrades Sagent Pharmaceuticals (SGNT -6.15%) on valuation, saying it's already reached the 12-month price target set when it initiated coverage three weeks ago. The stock is up 62% since its April IPO. Comment! [Healthcare, On the Move]
Wednesday, April 20, 2011, 9:55 AM Today's IPO pricings (actual vs. range): Mission NewEnergy (MNEL) $9 vs. $10-12, 2.8M shares. Sagent Pharma (SGNT) $16 vs. $14-16, 5.8M shares. Tesoro Logistics (TLLP) $21 vs. $19-21, 13M shares (currently +11% to $23.30). Comment! [On the Move]

SGNT Sagent Pharmaceuticals

SGNT

Sagent Pharmaceuticals